Corporate Governance

As Executive Chairman since November 2025 and President and CEO of Codexis from August 2022 until November 2025, Stephen has brought more than three decades of executive management experience in the biopharmaceutical industry. He currently serves as President, CEO and Board Chair of Sonoma Biotherapeutics, a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases. Prior to Codexis, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its sale to GlaxoSmithKline for $1.9 billion. Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestlé Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.

David V. Smith served as Chief Financial Officer and Executive Vice President of Five Prime Therapeutics, Inc., a public company focused on discovering and developing novel immune-oncology protein therapeutics that was acquired by Amgen, Inc. Previously, he was the Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology. Prior to IntegenX, he was the Executive Vice president and CFO of Thoratec Corporation, Vice President and CFO at Chiron Corp., Vice President and CFO of Anergen, Inc., and held various financial management positions with Genentech, Inc., IBM Corporation and Syntex Corporation. Mr. Smith previously served as a member of the board of directors of OncoGenex Pharmaceuticals Inc., a public biotechnology company. He received an MBA, specializing in finance from Golden Gate University and a BA in Economics and History from Willamette University.

Cynthia Collins has more than four decades of experience in the pharmaceutical and biotech industry. She most recently served as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision manufacturing platform until its acquisition by Medici Therapeutics in December 2025. Previously, she was the CEO of Editas Medicine from 2019 to 2021, where the first clinical trial administration of an in vivo CRISPR gene editing therapy took place under her leadership. Ms. Collins’ previous executive roles in biopharma include CEO of Human Longevity; CEO/general manager of various life science businesses at GE Healthcare; president and CEO of GenVec; group vice president at Beckman Coulter; CEO and president of Sequoia Pharmaceuticals; and president of Global Oncology at Baxter Healthcare. Earlier in her career, she served as President of Clinical Micro Sensors, Inc., then a subsidiary of Motorola. She began her career in various operating roles with Abbott Laboratories. Ms. Collins is a board member of Certara (CERT), MaxCyte (MXCT), DermTech (DMTK), Draper Laboratories, Alanis Therapeutics and Foundation for mRNA Medicines. She received her BS degree in microbiology from the University of Illinois, Urbana, and earned an MBA from The University of Chicago Booth School of Business.

Esther Martinborough has over two decades of drug discovery, research and development expertise in the life sciences industry. She served as Chief Scientific Officer at Escient Pharmaceuticals, a private biotechnology company, where she led a team responsible for the company’s discovery and early development pipeline from 2023 until the company was acquired by Incyte Corporation in 2024. She also served as VP of Research at Escient beginning in 2018. Prior to that, Dr. Martinborough served as Executive Director of Research at Receptos-Celgene from 2015 to 2018. From 2008 to 2015 she led the chemistry efforts at Receptos, respectively, where she was responsible for transforming a preclinical academic asset into a potential best-in-class blockbuster drug, Zeposia® (ozanimod), for multiple sclerosis and inflammatory bowel disease. Previously, Dr. Martinborough held positions at Vertex Pharmaceuticals, developing novel approaches to treating neuropathic pain, and at Ligand Pharmaceuticals, focusing on hormonal dysfunctions. She earned her MA from the University of California, Los Angeles, received her PhD from the Swiss Institute of Technology, Zurich, and was a post-doctoral Fellow at the University of Illinois, Urbana-Champaign.

Stewart Parker has over 30 years of experience in the biotechnology industry. Since January 2009, Ms. Parker has served as a Principal at Parker BioConsulting, a biotechnology consulting firm. From March 2011 to June 2014, Ms. Parker served in various roles at the Infectious Disease Research Institute, a not-for-profit global health research institute, including as its Chief Executive Officer, strategic advisor and a member of the Board of Directors. Prior to that, Ms. Parker served in various roles of leadership at biopharmaceutical companies since 1992, including as Chief Executive Officer of Targeted Genetics Corporation, a publicly-traded biopharmaceutical company, which she founded. Ms. Parker served on the Board of Directors of IMPEL Pharmaceuticals Inc., a publicly-traded pharmaceutical company, and currently serves as Board Chair of Sangamo Therapeutics, Inc., a publicly-traded genomic therapies company. Ms. Parker also currently serves on the Boards of Directors of various private companies. Previously, Ms. Parker served on the Boards of Directors of Achieve Life Sciences, Inc., a publicly traded pharmaceutical company, from August 2017 to May 2021, and Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.), a publicly-traded biotechnology company, from May 2019 to December 2020. Ms. Parker has also served on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker holds a BA in Slavic Language & Literature and an MBA in Finance and International Business from the University of Washington.

Christos Richards brings over 30 years of global executive advisory and search experience for the biopharmaceutical and healthcare industry to Codexis. To date, he has completed more than 450 executive level assignments, including over 200 board, CEO and CEO succession projects in the Life Sciences sector. He currently serves as Global Head of Healthcare and Life Sciences at Calibre One, a global executive search firm. Mr. Richards serves clients from venture-backed startups to leading global enterprises in devices, diagnostics, agricultural biotechnology, animal health, tools, services and digital health sectors. Prior to joining Calibre One, he served as a consultant with the global life sciences team at Spencer Stuart and a member of Spencer Stuart’s global Biopharma Board Practice. He has spent 20 years as a partner with two prominent boutique search firms, including serving as Chief Executive Officer of Levin & Company. Mr. Richards previously served on the Board of Directors for Coherus BioSciences and is also an advisor for the University of California, San Francisco Innovation Ventures Entrepreneurship Center. He holds a diploma in hospitality management from Schweizerische Wirteschule in Lucerne/Davos, Switzerland.

Rahul Singhvi is a global leader in the Life Sciences industry and has served as founder and CEO of Axella Biosciences, Inc. a private provider of technologies to deliver end-to-end CDMO services for biologicals and antibody drug conjugates since January 2025. Prior to Axella, he served as CEO and board member of the biomanufacturing company, Resilience, Inc. Prior to Resilience, Dr. Singhvi was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship’s innovation foundry, Flagship Venture Labs. Before joining Flagship, he was the Chief Operating Officer of Takeda’s Vaccine Business Unit where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. from 2005 to 2011 where he transformed the company from a specialty pharmaceutical business into a leading vaccine company. Rahul’s career began at Merck & Co in 1994, where he held several positions of increasing responsibility in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur in India and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Garuda Therapeutics and Kairos Pharma.

Raymond De Vré brings over 20 years of executive-level experience to Codexis. He founded and currently serves as CEO and Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) sector. He joined RADV from PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally, where he served as CEO until April 2023. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories from 2012 to 2021, including Senior Vice President, Global Business Operations and Strategy, Biologics and Vice President, Commercial Biologics. Earlier in his career, he held roles of increasing responsibility at McKinsey & Company, ultimately ascending to the role of Partner. Dr. De Vré holds a PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.